← Back to patent-cliff list
ABI-2280
Tier C — Watch / tradeABI-2280
Antiva Biosciences Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Not applicable
Indications (approved)：人乳头瘤病毒感染, Cervical intraepithelial neoplasia
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ABI-2280?
Approved indications include: 人乳头瘤病毒感染, Cervical intraepithelial neoplasia.
When does the ABI-2280 patent expire?
No public expiry year is available for ABI-2280 yet; this page updates once verified.
How do I get a quote for ABI-2280 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05